Foundation Medicine, Agios developing diagnostics for cancer drugs

04/5/2013 | GenomeWeb Daily News (free registration)

Foundation Medicine and Agios Pharmaceuticals agreed to jointly develop companion diagnostics for the latter's experimental cancer drugs. The two companies will seek to identify genomic mutations to determine which patients will benefit from Agios' new cancer metabolism inhibitors that target tumors with mutated IDH1 or IDH2 metabolic enzymes.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA